- Home
- BBNX vs VSTM Comparison
BBNX vs VSTM Comparison
Compare BBNX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBNX | VSTM |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | 423 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 395.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | BBNX | VSTM |
|---|---|---|
| Price | $15.85 | $6.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $23.80 | $16.50 |
| AVG Volume (30 Days) | 994.2K | ★ 3.1M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | $34.90 | $282.64 |
| Revenue Next Year | $34.63 | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $8.80 | $3.43 |
| 52 Week High | $32.71 | $11.25 |
Technical Indicators
Market Signals| Indicator | BBNX | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 66.74 |
| Support Level | $9.34 | $5.77 |
| Resistance Level | $32.52 | $6.48 |
| Average True Range (ATR) | 1.17 | 0.48 |
| MACD | -0.25 | 0.08 |
| Stochastic Oscillator | 18.16 | 87.28 |
Price Performance
Historical ComparisonAbout BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.